慢性肾脏病-矿物质和骨异常影像学进展:功能成像的应用前景
本文综述慢性肾脏病-矿物质和骨异常(CKD-MBD)的影像学评估,指出骨活检、骨显像、生化标志物和平片各有局限。功能成像无创且比血清标志物更特异,18F-NaF PET/CT 因骨摄取高、单次通过提取快、与血清蛋白结合少,优于传统骨扫描,可评估骨骼代谢及治疗前后变化,并描述了CKD相关肌肉骨骼改变的闪烁/功能成像表现模式。
要点
- 18F-NaF PET/CT 在CKD患者中优于传统骨扫描,可评估全骨骼代谢。
- 功能成像无创且比血清标志物更特异,适合评估总体骨骼代谢。
- 本文描述CKD相关肌肉骨骼改变的闪烁/功能成像表现模式。
关键影像表现/征象
- 本文描述CKD相关肌肉骨骼改变的闪烁/功能成像表现模式。
诊断标准与关键数值
- 18F-NaF PET/CT 因骨摄取高、单次通过提取快、与血清蛋白结合少,优于传统骨扫描。
- 功能成像比血清标志物更特异,可评估总体骨骼代谢。
临床应用与阅片要点
- 在CKD患者中可优先考虑18F-NaF PET/CT评估骨骼代谢,优于传统骨扫描。
- 功能成像可用于初诊评估及治疗后随访骨骼代谢变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Disorders of mineral metabolism and bone disease are common complications in chronic kidney disease (CKD) patients and are associated with increased morbidity and mortality. Bone biopsies, bone scintigraphy, biochemical markers, and plain films have been used to assess bone disorders and bone turnover. Of these, functional imaging is less invasive than bone/marrow sampling, more specific than serum markers and is therefore ideally placed to assess total skeletal metabolism. 18F-sodium fluoride (NaF) PET/CT is an excellent bone-seeking agent superior to conventional bone scan in CKD patients due to its high bone uptake, rapid single-pass extraction, and minimal binding to serum proteins. Due to these properties, 18F-NaF can better assess the skeletal metabolism on primary diagnosis and following treatment in CKD patients. With the increased accessibility of PET scanners, it is likely that PET scanning with bone-specific tracers such as 18F-NaF will be used more regularly for clinical assessment and quantitation of bone kinetics. This article describes the pattern of scintigraphic/functional appearances secondary to musculoskeletal alterations that might occur in patients with CKD.
引用
- Usmani S, Ahmed N, Gnanasegaran G, et al. Update on imaging in chronic kidney disease-mineral and bone disorder: promising role of functional imaging. Skeletal Radiol. 2021. PMID: 34524489. doi:10.1007/s00256-021-03905-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。